Therapeutic Antibodies

Therapeutic Antibodies
a tsunami of therapeutics? -- a panel discussion

moderated by David Palella
Founder, Bioscience Ventures Inc.

Wednesday, January 18, 2012, 5:30-8:30 pm

San Diego became a therapeutic (Rx) & diagnostic (Dx) antibody (Ab) mecca with the founding of Hybritech in 1978 (later acquired by Eli Lilly), and the subsequent founding by several of the same people of IDEC Pharmaceuticals in 1985, which merged with Biogen in 2003. The success of both companies created dozens of experienced managers and millionaire scientists who went on to start other San Diego antibody biotechs such as Biosite Inc. -- thus creating 1,000s of other San Diego jobs.

Today approximately 30 Rx Abs are FDA approved and had annual sales of about US$ 37 billion in 2010. Sales are expected to grow at least 10 - 15 % annually through 2020, the highest growth rate of any Rx drug category.

With their faster development times and lower clinical risks, therapeutic antibodies (Rx Abs) are still an attractive investment theme for VCs worldwide -- even 30 years later.

Moreover, today antibodies aren't just for biochemists' breakfast anymore! -- rather, chemists too can also join in the vocational fun by adding small-molecule, peptide or radioactive payloads to Rx Abs, or by designing new chemical linkers and polymeric drug delivery systems for Abs or Ab fragments.

Thus, Rx Abs offer a faster, proven and lower-risk route to value creation in tough investment and economic environments, as well as a more stable career path for open-minded scientists of any technical specialty.

So what's new in the Rx Ab community in San Diego ? Our panel of Ab savants and entrepreneurs will discuss the future prospects for Rx Abs in San Diego -- and the possibility that once again San Diego could be home to another Ab powerhouse such as Hybritech, IDEC or Biosite!

PANELISTS:

(1) Roland A. NEWMAN, Ph.D.
VP & CSO, Tanabe Research Laboratory (TRL)
[ a subsidiary of MITSUBISHI TANABE PHARMACEUTICAL CORP. ]
San Diego, Calif.
Roland Newman Ph.D. joined Tanabe Research Laboratories USA as Chief Scientific Officer in the spring of 2010. Before joining TRL he was Principal at RANA Consulting, a biotechnology consulting company with special emphasis on Japanese-US pharmaceutical partnering. Prior to this was head of the Molecular Immunology Department at Idec Pharmaceuticals and then Senior Director of Business Development at Biogen-Idec. During his time at Idec he was co-inventor of Rituxan® and co-developed several other therapeutic antibodies for oncology and autoimmune diseases. Dr. Newman's scientific experience covers immunology, molecular biology and biochemical research in both academic and industrial environments and he has over 100 peer reviewed publications, several book chapters and 30 patents. Prior to his industrial experience Dr. Newman was Assistant Professor at the University of California San Diego and visiting scientist at the Salk Institute in San Diego. He obtained his Ph.D. in the UK at the University of Bath and did post-doctoral research at the Imperial Cancer Research Fund laboratories in London and the University Medical Clinic in Cologne Germany.
http://www.trlusa.com
http://www.mt-pharma.co.jp/e/index.php

(2) Mohit “Mo” Trikha, Ph.D.
CSO & VP Early Development at Triphase Accelerator
Dr. Trikha has >15 yrs of drug development experience. Previously, Dr. Trikha was Associate VP Clinical Development at Ambit, Director BioOncology Early Development at Genentech, and Associate Director of Oncology at Centocor (JNJ). At Ambit, he was responsible for translational medicine and project management. At Genentech, he was responsible for BioOncology Early Development of mAbs, ADCs and SMIs. At Centocor, he focused on angiogenesis, inflammation, immunoliposomes, and mAbs. Dr Trikha has been involved in 12 INDs, initiated multiple clinical trials and has been the head of translational medicine, PM, diagnostics and biometrics. He has worked on CNTO 328 (anti-IL6), CNTO 95 (anti-integrin), Herceptin-DM1, anti-CD22 drug conjugate, MetMab (anti-cMET), GDC 0941 (PI3Kinase), GDC 0449 (Hedgehog), AC220 (FLT3 kinase), and AC480 (pan-HER). Currently, he advises several antibody companies and UCSF QB3. Dr. Trikha has multiple patents, published 32 papers and presented at multiple international meetings. He has a PhD from USC and was an Assistant Professor (Research) at WSU/Karmanos Cancer Institute.
http://www.linkedin.com/pub/mo-trikha/8/133/977

(3) Charles Theuer, PhD
President and CEO, TRACON Pharmaceuticals
San Diego, CA
Dr. Theuer joined TRACON as President, Chief Executive Officer, and a board member in July 2006. From 2004 to 2006, Dr. Theuer was Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc. where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer was the Director of Clinical Oncology at Pfizer, where he led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals and the National Cancer Institute where he was involved in the development of multiple small molecules and monoclonal antibody therapies. Dr. Theuer holds a B.S. from MIT, an M.D. from UC San Francisco, and a Ph.D. from UC Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center. Dr. Theuer has held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
http://www.traconpharma.com/
http://www.linkedin.com/pub/charles-theuer/2/911/130

(4) Peggy Marino, Ph.D.
Sr. Director, External R&D Innovation
BioTherapeutics Unit, Pfizer, Inc.
San Diego, CA
Dr. Marino recently relocated to San Diego, CA in the spring of 2010 to join the global Pfizer External R&D Innovation group with the role to scout for potential external therapeutic assets and technologies in the area of biotherapeutics and to establish innovative collaborations with Biotechs and academic partners. Previously, Peggy was the Site Lead for the Pfizer St. Louis laboratories for the External Research Solutions group supporting the Inflammation, Biotherapeutics and Medicinal Chemistry research units. Dr. Marino has over 25 years experience in drug discovery research in large Pharma leading technology-based research groups in areas such as genomics and molecular technologies, protein biochemistry, in vitro pharmacology, highthroughput screening, and structural and analytical chemistry. As Senior Director of the Primary Pharmacology, Protein and Molecular Technologies, and BioAnalytical Chemistry groups in Pfizer, Peggy was responsible for supporting the Therapeutic portfolios in both small molecule and biotherapeutics. Prior to joining Pfizer in 2003, Dr. Marino previously held Sr. Director level positions in Pharmacia and Searle Pharmaceuticals. Peggy obtained her Ph.D. from Pennsylvania State University in organic chemistry and went on to do postdoctoral work in molecular biology prior to joining industry.
http://www.linkedin.com/pub/margaret-marino/4/b5b/b7

Location Sponsor:

AMN logo 12400 High Bluff Drive
San Diego, CA 92130


Map

Registration online : $25 (until January 17), $15 student/affiliate/in transition
Onsite $30, $20 student/affiliate/in transition
Admission includes a light dinner and drinks from 5:30 – 6:30 pm. Program begins at 6:30 pm

choose ticket